Advanced Therapies Integrates 2021 Track 3
PRODUCE AND USE
Welcome and opening remarks
Making Waves: Technologies and development improvements
How good are we at making Advanced Therapies today, what should the future look like?
Focusing on manufacturing technologies and analytical methods and the role of high throughput and automation
JASON C. FOSTER | Chief Executive Officer and Executive Director | Ori Biotech
DAVID BLAKEY | Senior Vice President Strategic Alliances | MiNA Therapeutics
BRIAN HARRISON | Managing Director | HiTech Health
JAMES KUSENA | Head of Bioprocessing | MicrofluidX
KRZYSZTOF POTEMPA | Founder and CEO | BRAINCURES
KEITH MUIR | Founder & Director | Cytomos
As more ATMPs progress towards the market, there are significant emergent challenges to the supply chain. What needs to happen to ensure therapies are effectively and efficiently produced?
SHARON BROWNLOW | Chief Business Officer | Cell and Gene Therapy Catapult
ROBERT JONES | Vice President, Global BioServices | Cryoport Systems
MARK FOWLER | Global Head of Procurement | Autolus
DAN PEARCE | Vice President, European Manufacturing & Technical Operations | Adaptimmune
SADIA L’BAOUCH | Chief Technical Officer, Vice President | Ixaka
As manufacturing technologies continue to emerge, we must have the skills to deliver the science at scale. How can we ensure that talent tracks with emergent manufacturing trends?
Due process: GMP translation and manufacture
Shortening upstream and downstream process is key to cost and natural resource savings and efficiencies for ATMPs. Can we share knowledge for the greater good of patients and the planet?
SIMON PEGG |Director | Project-Ion
NAZNEEN RAHMAN | Founder and Chief Executive Officer | YewMaker
JASON DOWD | Vice-President of Science & Technology | CCRM
WILLIAM ‘BILL’ SCOTT | Scientific Director, Transplant Regenerative Medicine | Newcastle University Medical School
STEVEN TAIT | Business Manager | LifeArc
HARVEY BRANTON | Technology Lead | CPI Biologics
Negotiate or collaborate?
In an ever-changing pharmaceutical landscape, successfully bringing a concept to market — and to patients — involves many different stakeholders. How do industry leaders navigate this journey most effectively?
KATHRYN SIMPSON | Business Consultant| Kathryn Simpson Consulting
MALCOLM BARRATT-JOHNSON | Managing Director | PharmaMedic Consultancy Ltd
TERRI GASKELL | Chief Technical Officer | Rinri Therapeutics Ltd.
EMILY MERRELL | Interim Head of ATTC Network Coordination | Cell and Gene Therapy Catapult
NADINE CLEMO | Drug Discovery Program Director | Apollo Therapeutics